
Dishoom is opening a tiny hotel in London
If you're not familiar with Dishoom, where have you been? Since opening its first spot in Covent Garden in 2010, the elevated Indian joint has become one of London's most dependable chains. Inspired by Bombay cafés of the 20th century, its most popular dishes include a creamy black daal, a rich 'chicken ruby' curry and egg and bacon breakfast naans.
Soon two bedrooms will be available to rent above the new all day bar-café, which officially opens on Friday, May 9. Dishoom founders Shamil Thakrar and Kavi Thakrar told Bloomberg that the rooms aren't quite finished yet, and they are still deciding how much each one will go for, and how long the minimum stay will be, although it's likely to be a two-night minimum with a maximum of one week. 'We don't want it to be so expensive people can't afford it,' Kavi said.
The founders suggested that residents in the hotel rooms might be able to have food from the restaurant delivered to their rooms, but this is not confirmed yet, while guests will have priority booking of the downstairs tables.
'The concept of having bacon naan first thing in the morning when you roll out of bed in your pj's is alluring,' Kavi told Bloomberg. 'We imagine people sitting on the sofa and having food delivered to them.'
Dishoom already has Permit Rooms in Brighton, Cambridge and Oxford, but this will be the first to open in the capital. Dishoom describes its sister brand as 'a salute to Bombay's permit rooms, beer bars and drinking holes' – bars that opened in the Indian capital in the 1970s after prohibition was lifted.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Reuters
2 hours ago
- Reuters
KKR in talks to buy ST Telemedia Global Data Centres, Bloomberg News reports
July 26 (Reuters) - KKR (KKR.N), opens new tab is in talks to buy ST Telemedia Global Data Centres in a deal that could value the Asian digital infrastructure provider at more than $5 billion, Bloomberg News reported on Saturday, citing people familiar with the matter. Reuters could not immediately verify the report.

South Wales Argus
7 hours ago
- South Wales Argus
Cwmbran: Tandoorz takeaway awarded five-star hygiene rating
Tandoorz, located in Fairwater Square, opened on June 5 and was inspected on June 25. The takeaway, which serves kebabs, wraps, curries, and Indian-flavoured pizzas, was rated as "good" in both hygienic food handling and cleanliness and condition of facilities and building. In their management of food safety, they received a "very good" rating. A spokesperson for Tandoorz said: "We had our first visit from Torfaen environmental health, and we are delighted to have achieved a five-star rating. "Many thanks to all our already growing loyal customers for your support, and great thanks to the Tandoorz team. "Our kitchen is open plan, so everyone is welcome to come and see their meals being cooked fresh in front of them by our skilled chefs. "We also have lots of collection-only deals." Tandoorz offer a variety of dishes including donner kebabs in plain, tandoori, or naga flavours, and chicken tikka kebabs made from fresh marinated chicken breast cooked on the chargrill. All their kebabs and wraps are served using fresh naan cooked in the tandoor oven. They also offer traditional curries and Indian-flavoured pizzas. Customers have the option to order online at where they can get 10 per cent off and collect loyalty points. The food hygiene rating is based on three areas: hygienic food handling, cleanliness and condition of facilities and building, and management of food safety. The rating ranges from 0, which means urgent improvement is required, to 5, which means hygiene standards are very good. The inspection is carried out by officers from the food safety team at the council.


ITV News
9 hours ago
- ITV News
UK-India trade deal sparks fears over access to cheap medicines for millions
A newly signed trade agreement between India and the UK has triggered concerns that millions of poor Indians may lose access to affordable life-saving medicines. Civil society groups and health experts say the UK-India Free Trade Agreement (FTA), finalised between two countries, tilts the balance in favour of multinational pharmaceutical corporations and threatens to erode long-standing protections that have allowed India to produce low-cost generic drugs. 'This is not just about trade. It's about whether a person living on ₹200 (£2) a day can afford cancer treatment or survive tuberculosis,' said Jyotsna Singh, co-convenor of the Working Group on Access to Medicines and Treatments. At the heart of the controversy are the agreement's intellectual property (IP) provisions, which activists say may restrict the Indian government's ability to issue compulsory licences—legal tools that allow domestic companies to manufacture patented drugs at reduced prices during public health emergencies. India used this provision in 2012 to dramatically cut the price of sorafenib, a cancer drug sold by Bayer under the brand Nexavar. Generic versions slashed the monthly cost by nearly 97%, from ₹2.8 lakh (£2,600) to around ₹8,800 (£80), making it affordable to thousands. 'By discouraging compulsory licensing and promoting voluntary licences, the deal hands over control of access to medicines to the market,' said Prof Biswajit Dhar, a trade expert and former professor at New Delhi's Jawaharlal Nehru University. 'Voluntary licences often come with strings attached and don't bring the same price reductions.' Weakening India's Patent Safeguards Under the FTA, companies will no longer need to report annually how their patents are being 'worked'—or used—in India. Instead, disclosures can be made every three years, and some information can be kept confidential. Activists say this undermines transparency and makes it harder to prove that a drug isn't available to the public, a key step in applying for a compulsory licence. There are also concerns the deal could open the door to 'evergreening'—a tactic in which companies make minor changes to existing drugs and claim new patents. Indian law currently limits this practice under Section 3(d) of the Patents Act, but experts warn the FTA's emphasis on 'harmonisation' of IP standards with Western countries could override such protections. 'This is effectively a backdoor entry for TRIPS-plus provisions,' said K.M. Gopakumar, co-convenor of the Working Group. 'It would push India to grant unnecessary patents, prolonging monopolies and delaying cheaper alternatives.' The Indian pharmaceutical industry supplies more than 60% of global vaccines and a significant share of affordable generics to low- and middle-income countries. Critics say the FTA may limit this capacity and ultimately have consequences well beyond India's borders. Government response The Indian government has promoted the FTA as a landmark deal that will boost exports and attract UK investment in manufacturing, services, and digital trade. Officials insist that India has preserved its ability to protect public health. But rights groups remain unconvinced. 'You cannot negotiate away access to life-saving drugs in the name of free trade,' said Gargeya Telakapalli, a public health campaigner based in Hyderabad. 'The poorest Indians—those with cancer, HIV, diabetes, or TB—are being quietly sacrificed.' Broader implications The deal follows a similar agreement India signed last year with the European Free Trade Association (EFTA), which also faced criticism for diluting IP safeguards. Observers say the trend may reflect a shift in India's trade policy as it seeks closer ties with Western economies. But for many in India's healthcare and legal communities, the question remains: how much access to medicine is the country willing to give up for a better trade balance? From Westminster to Washington DC - our political experts are across all the latest key talking points. Listen to the latest episode below...